Impax Asset Management Group plc acquired a new position in Solventum Corporation (NYSE:SOLV – Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 21,613 shares of the company’s stock, valued at approximately $1,905,000.
Other large investors have also recently added to or reduced their stakes in the company. HighTower Advisors LLC increased its holdings in Solventum by 3.0% during the 3rd quarter. HighTower Advisors LLC now owns 31,130 shares of the company’s stock valued at $2,744,000 after acquiring an additional 920 shares in the last quarter. BCS Private Wealth Management Inc. raised its position in Solventum by 9.7% during the third quarter. BCS Private Wealth Management Inc. now owns 6,267 shares of the company’s stock worth $552,000 after acquiring an additional 555 shares during the last quarter. White Pine Capital LLC purchased a new stake in shares of Solventum in the third quarter valued at about $2,195,000. Bessemer Group Inc. lifted its holdings in shares of Solventum by 39.1% in the third quarter. Bessemer Group Inc. now owns 2,100 shares of the company’s stock valued at $184,000 after purchasing an additional 590 shares in the last quarter. Finally, AlTi Global Inc. lifted its holdings in shares of Solventum by 15.0% in the third quarter. AlTi Global Inc. now owns 4,203 shares of the company’s stock valued at $370,000 after purchasing an additional 547 shares in the last quarter.
Analyst Ratings Changes
Several analysts have recently commented on SOLV shares. Benchmark reiterated a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. Stifel Nicolaus raised their price objective on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. UBS Group lifted their price objective on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. KeyCorp upped their target price on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $90.27.
Read Our Latest Research Report on Solventum
Solventum Trading Up 0.4%
Solventum stock opened at $86.43 on Thursday. The stock has a market cap of $14.67 billion, a PE ratio of 97.11, a P/E/G ratio of 1.22 and a beta of 0.69. The stock has a 50-day moving average price of $87.32 and a 200 day moving average price of $79.11. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $94.16. The company has a current ratio of 1.03, a quick ratio of 0.72 and a debt-to-equity ratio of 0.99.
Solventum (NYSE:SOLV – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.11. The firm had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.50 EPS. Equities research analysts predict that Solventum Corporation will post 7.26 earnings per share for the current fiscal year.
Solventum Profile
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
Further Reading
- Five stocks we like better than Solventum
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
